lactose placebo-Sunnybrook Health Sciences Centre-fracture

The lactose placebo-Sunnybrook Health Sciences Centre-fracture refers to the inactive control substance used in the Lithium for Fracture Treatment (LiFT) trial, a Phase 2 double-blind randomized controlled trial sponsored by Sunnybrook Health Sciences Centre. The placebo is formulated as lactose capsules designed to be indistinguishable from the active treatment, 300 mg lithium carbonate, to maintain the integrity of the study blinding. The trial investigates whether a short course of low-dose lithium can enhance the healing of long bone fractures (such as the femur, tibia, humerus, or clavicle) in healthy adults. Administered orally once daily for two weeks starting 14 days after the fracture or surgery, this placebo has no active pharmacological ingredients and no biological targets, serving strictly as a comparator to evaluate the efficacy of the lithium intervention.

Other names

Lactose Placebo